17985-82-9 Usage
Description
2-[5-hydroxy-4-(hydroxymethyl)-6-methylpyridin-3-yl]ethylphosphonic acid, also known as alendronic acid, is a synthetic bisphosphonate compound utilized in the medical field for the treatment of osteoporosis and other bone-related disorders. It functions by inhibiting osteoclast activity, thus preventing bone loss and enhancing bone density, which in turn reduces the risk of fractures. Alendronic acid is typically taken orally and has demonstrated effectiveness in both men and women, although it may cause potential side effects such as gastrointestinal irritation, esophageal ulcers, and musculoskeletal pain. It is crucial to adhere to the prescribed dosing regimen and consume the medication with ample water to minimize the risk of adverse effects.
Uses
Used in Pharmaceutical Applications:
Alendronic acid is used as a therapeutic agent for the treatment of osteoporosis and other bone-related disorders. It works by inhibiting the activity of osteoclasts, the cells responsible for breaking down bone tissue, thereby preventing bone loss and improving bone density. This action reduces the risk of fractures and is effective in both men and women.
Used in Orthopedic Applications:
In the orthopedic industry, alendronic acid is used as a medication to manage and treat bone-related conditions, such as osteoporosis, which can lead to an increased risk of fractures. By improving bone density and reducing bone loss, alendronic acid helps to enhance the overall strength and resilience of the skeletal system, providing support and stability to patients with bone-related disorders.
Used in Geriatric Applications:
Alendronic acid is also used in geriatric applications to address age-related bone loss and the increased risk of fractures associated with osteoporosis in older adults. By improving bone density and reducing bone loss, alendronic acid can help maintain the overall health and integrity of the skeletal system in geriatric patients, reducing the risk of fractures and improving their quality of life.
Check Digit Verification of cas no
The CAS Registry Mumber 17985-82-9 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,7,9,8 and 5 respectively; the second part has 2 digits, 8 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 17985-82:
(7*1)+(6*7)+(5*9)+(4*8)+(3*5)+(2*8)+(1*2)=159
159 % 10 = 9
So 17985-82-9 is a valid CAS Registry Number.
17985-82-9Relevant articles and documents
Vitamin B6 analogs. 4. 4-Desoxyisopyridoxal and the phosphonic acid analog of 4-desoxypyridoxine phosphate.
Struck,Shealy,Montgomery
, p. 568 - 571 (1971)
-
Synthesis of hydrolysis-resistant pyridoxal 5′-phosphate analogs and their biochemical and X-ray crystallographic characterization with the pyridoxal phosphatase chronophin
Knobloch, Gunnar,Jabari, Nauras,Stadlbauer, Sven,Schindelin, Hermann,K?hn, Maja,Gohla, Antje
, p. 2819 - 2827 (2015/03/30)
A set of phosphonic acid derivatives (1-4) of pyridoxal 5′-phosphate (PLP) was synthesized and characterized biochemically using purified murine pyridoxal phosphatase (PDXP), also known as chronophin. The most promising compound 1 displayed primarily competitive PDXP inhibitory activity with an IC50 value of 79 μM, which was in the range of the Km of the physiological substrate PLP. We also report the X-ray crystal structure of PDXP bound to compound 3, which we solved to 2.75 ? resolution (PDB code 5AES). The co-crystal structure proves that compound 3 binds in the same orientation as PLP, and confirms the mode of inhibition to be competitive. Thus, we identify compound 1 as a PDXP phosphatase inhibitor. Our results suggest a strategy to design new, potent and selective PDXP inhibitors, which may be useful to increase the sensitivity of tumor cells to treatment with cytotoxic agents.
